Predict your next investment

Nephera company logo
HEALTHCARE | Medical Devices & Equipment / Patient Monitoring
nephera.com

See what CB Insights has to offer

Stage

Series B | Alive

Total Raised

$2.85M

Last Raised

$2.85M | 11 yrs ago

About Nephera

Nephera offers a treatment for acute heart failure patients by protecting kidney function through the modulation of sympathetic nerve activity. The Company's unique technology, in the exciting field of neurohormonal modulation, is based on electrical stimulation of the urinary tract for controlled inhibition of renal sympathetic nerve activity. The clinical outcome is preserved renal function and enhanced diuretic therapy.

Nephera Headquarter Location

Israel

Latest Nephera News

Nephera, of the Misgav Venture Accelerator, Raises $2.85 million

Oct 6, 2015

Aurum Ventures, Evergreen, and the Trendlines Group Took Part in the Investment August 11, 2010 09:28 AM Eastern Daylight Time MISGAV, Israel--( BUSINESS WIRE )--Nephera, a medical device company that was started in the Misgav Venture Accelerator, today completed its second round of capitalization, in which it raised $2.85 million. Aurum Ventures, Evergreen Venture Partners, and the Trendlines Group (through its Misgav Venture Accelerator unit) took part in this round. The investment will enable Nephera to launch clinical trials of its device for the treatment of patients suffering from congestive heart failure (CHF). The device, designed to improve and maintain kidney function during these patients’ frequent hospitalizations, is based on electrical stimulation of the urinary system. At present, the decline in kidney function during hospitalization causes a deterioration in the patient’s overall condition. The company successfully completed a round of pre-clinical trials recently and is expected to begin clinical trials in the coming months. Nephera CEO Gill Bar-Yoseph said: “We are encouraged by the success of the investment round and thank the investors for their confidence in the company and in its product. Nephera’s solution for CHF patients is a breakthrough, especially as the prevalence of the illness has been increasing over the years. We intend to start clinical trials as soon as possible.” According to Dr. Ronit Bendori of Evergreen Venture Partners, “The solution proposed by Nephera is unique in its simplicity and in its ability to treat a heart problem via a peripheral system, namely, the urinary system. The product developed by the company has a growing target population of CHF patients and can lead to a dramatic change in this area.” “Having witnessed the success of the pre-clinical trials,” said Dr. Dan Gelvan of Aurum Ventures, ”we believe that, together with the company’s management, we will succeed in obtaining good results in clinical trials and soon reach the stage of sales.” CHF is a major problem in industrialized countries. In the United States alone, more than a million people are hospitalized each year due to CHF; in fact, it is the leading cause of hospitalization among older patients in the US. The prevalence of the disease has increased over the years, partly due to improved medical care and the consequent rise in life expectancy. ABOUT NEPHERA Nephera was established in the Misgav Venture Accelerator in 2008. It is developing a device to treat patients suffering from congestive heart failure based on electrical stimulation of the urinary system. The company recently completed a round of pre-clinical trials and is expected to begin clinical trials in the near future. ABOUT MISGAV The Misgav Venture Accelerator ( http://www.misgav-venture.com ), founded in 1992, specializes in medical instrumentation, pharmaceutical, and biotechnology companies. Recently, it was named “Best Incubator” of 2009 by the Chief Scientist. The Israeli Trendlines Group owns a controlling interest in the accelerator. ABOUT AURUM VENTURES Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent businessman, philanthropist, and entrepreneur. Aurum invests in life-sciences and cleantech companies based in or connected to Israel, in all stages of development. ABOUT EVERGREEN Evergreen Venture Partners, founded in 1987, has become a leader in the Israeli venture capital market. It invests in startups specializing in software, the Internet and new media, communications, and the life sciences, remaining with them throughout their lives starting with the initial stages. Evergreen manages $700 million in venture capital funds and has so far invested in more than 120 startups. Evergreen has had 37 successful exits involving stock issues or the sale of companies, including Exalink, BigBand, Traiana, Colbar, Identify, and Dune. For further information, please visit the company’s website: www.evergreen.co.il . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nephera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nephera is included in 2 Expert Collections, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Bioelectronics

1,099 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

Nephera Patents

Nephera has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/20/2014

11/22/2016

Progestogens, Synthetic estrogens, Urinary system, Estranes, Abandoned drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/20/2014

00/00/0000

00/00/0000

Grant Date

11/22/2016

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Progestogens, Synthetic estrogens, Urinary system, Estranes, Abandoned drugs

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Nephera Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nephera Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.